Last reviewed 2026-05-31 · How we verify

(+/-)-Moprolol (MOPROLOL)

Phase 2 active Small molecule ✓ Verified May 2026

(+/-)-Moprolol (generic name: MOPROLOL) is a moprolol drug. It is currently in Phase 2 development.

Moprolol works by interacting with beta-adrenergic receptors in the body.

(+/-)-Moprolol is a small molecule with synonyms including Levomoprolol, Moprolol, and Moprolol L-Form.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MOPROLOL
Drug class	moprolol
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your body's 'fight or flight' response is like a car accelerator pedal. Beta-adrenergic receptors are like the pedal itself, and moprolol helps to slow down or speed up the signal that tells the pedal to accelerate. This can help to regulate heart rate and blood pressure.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(+/-)-Moprolol CI brief — competitive landscape report
(+/-)-Moprolol updates RSS · CI watch RSS

Frequently asked questions about (+/-)-Moprolol

What is (+/-)-Moprolol?

(+/-)-Moprolol (MOPROLOL) is a moprolol drug.

How does (+/-)-Moprolol work?

Moprolol works by interacting with beta-adrenergic receptors in the body.

What is the generic name of (+/-)-Moprolol?

MOPROLOL is the generic (nonproprietary) name of (+/-)-Moprolol.

What drug class is (+/-)-Moprolol in?

(+/-)-Moprolol belongs to the moprolol class. See all moprolol drugs at /class/moprolol.

What development phase is (+/-)-Moprolol in?

(+/-)-Moprolol is in Phase 2.

Drug class: All moprolol drugs
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing